BioCentury | Jan 8, 2021
Management Tracks

PacBio hires pair of Illumina vets; plus Ionis, Sana, Purespring, eFFECTOR, Constellation, T2, MiNA, Vividion, Pharma Two B and WIB

...N.V. (Euronext:PHARM).Patricia “Patty” Allen joined oncology and immunology company Vividion Therapeutics Inc. as acting CFO.Israeli Parkinson’s play Pharma Two B Ltd....
...of its Research Triangle Park, N.C., chapter. BC Staff Ionis Pharmaceuticals Pacific Biosciences Sana Biotechnology Purespring Therapeutics eFFECTOR Therapeutics Constellation Pharmaceuticals Vividion T2 Biosystems MiNA Therapeutics Pharma Two B Women...
BioCentury | May 26, 2020
Deals

With trio of COVID deals, Merck takes a page from its Ebola strategy

Merck’s strategy to tackle COVID-19 appears to echo an approach that allowed the pharma to rapidly develop a vaccine for Ebola -- but on a much faster timeline. Merck & Co. Inc. (NYSE:MRK) said Tuesday...
BioCentury | Mar 2, 2017
Financial News

Pharma Two B completes venture financing

...Drug combination and neurology company Pharma Two B Ltd. (Rehovot, Israel) raised $30 million in its third financing round...
...and JVC. Existing investors JK&B and Generali Financial Holdings also participated. Pharma Two B Ltd. , Rehovot, Israel Alex Himes Pharma Two B Ltd....
BioCentury | Aug 3, 2015
Clinical News

P2B001: Phase IIb data

...to reference data on safety and efficacy from scientific literature or from previously approved products. Pharma Two B Ltd....
BioCentury | Mar 9, 2015
Clinical News

P2B001: Completed Phase IIb enrollment

...to reference data on safety and efficacy from scientific literature or from previously approved products. Pharma Two B Ltd....
BioCentury | Mar 24, 2014
Clinical News

P2B001: Phase IIb started

...rights to the product in China, South Korea, Hong Kong, Malaysia, Thailand and the Philippines. Pharma Two B Ltd....
BioCentury | Nov 19, 2012
Financial News

Pharma Two B completes venture financing

Pharma Two B Ltd. , Rehovot, Israel Business: Neurology, Cancer, Endocrine/Metabolic Date completed: 10/22/12 Type: Venture financing Raised: $8 million WIR Staff cancer Neurology...
BioCentury | Aug 6, 2012
Strategy

Freedom to deal Strategy

Idenix Pharmaceuticals Inc. believes it is finally positioned to become a player in the race for an all-oral HCV regimen after restructuring its nine-year old collaboration with Novartis AG . But by now several large HCV...
BioCentury | Mar 5, 2012
Product Development

Dynamic duo

Novartis AG 's deal with Enanta Pharmaceuticals Inc. gives the pharma two angles for targeting HCV that act directly and indirectly against the non-structural protein 5A. The combination of Enanta's direct inhibitor with the pharma's...
BioCentury | Apr 18, 2011
Finance

Ripening fund for Israel

OrbiMed Advisors had a $203 million close for its OrbiMed Israel Partners healthcare fund. The firm is continuing to raise money, working toward an undisclosed target. The Israeli government is an LP, contributing about $40...
Items per page:
1 - 10 of 10
BioCentury | Jan 8, 2021
Management Tracks

PacBio hires pair of Illumina vets; plus Ionis, Sana, Purespring, eFFECTOR, Constellation, T2, MiNA, Vividion, Pharma Two B and WIB

...N.V. (Euronext:PHARM).Patricia “Patty” Allen joined oncology and immunology company Vividion Therapeutics Inc. as acting CFO.Israeli Parkinson’s play Pharma Two B Ltd....
...of its Research Triangle Park, N.C., chapter. BC Staff Ionis Pharmaceuticals Pacific Biosciences Sana Biotechnology Purespring Therapeutics eFFECTOR Therapeutics Constellation Pharmaceuticals Vividion T2 Biosystems MiNA Therapeutics Pharma Two B Women...
BioCentury | May 26, 2020
Deals

With trio of COVID deals, Merck takes a page from its Ebola strategy

Merck’s strategy to tackle COVID-19 appears to echo an approach that allowed the pharma to rapidly develop a vaccine for Ebola -- but on a much faster timeline. Merck & Co. Inc. (NYSE:MRK) said Tuesday...
BioCentury | Mar 2, 2017
Financial News

Pharma Two B completes venture financing

...Drug combination and neurology company Pharma Two B Ltd. (Rehovot, Israel) raised $30 million in its third financing round...
...and JVC. Existing investors JK&B and Generali Financial Holdings also participated. Pharma Two B Ltd. , Rehovot, Israel Alex Himes Pharma Two B Ltd....
BioCentury | Aug 3, 2015
Clinical News

P2B001: Phase IIb data

...to reference data on safety and efficacy from scientific literature or from previously approved products. Pharma Two B Ltd....
BioCentury | Mar 9, 2015
Clinical News

P2B001: Completed Phase IIb enrollment

...to reference data on safety and efficacy from scientific literature or from previously approved products. Pharma Two B Ltd....
BioCentury | Mar 24, 2014
Clinical News

P2B001: Phase IIb started

...rights to the product in China, South Korea, Hong Kong, Malaysia, Thailand and the Philippines. Pharma Two B Ltd....
BioCentury | Nov 19, 2012
Financial News

Pharma Two B completes venture financing

Pharma Two B Ltd. , Rehovot, Israel Business: Neurology, Cancer, Endocrine/Metabolic Date completed: 10/22/12 Type: Venture financing Raised: $8 million WIR Staff cancer Neurology...
BioCentury | Aug 6, 2012
Strategy

Freedom to deal Strategy

Idenix Pharmaceuticals Inc. believes it is finally positioned to become a player in the race for an all-oral HCV regimen after restructuring its nine-year old collaboration with Novartis AG . But by now several large HCV...
BioCentury | Mar 5, 2012
Product Development

Dynamic duo

Novartis AG 's deal with Enanta Pharmaceuticals Inc. gives the pharma two angles for targeting HCV that act directly and indirectly against the non-structural protein 5A. The combination of Enanta's direct inhibitor with the pharma's...
BioCentury | Apr 18, 2011
Finance

Ripening fund for Israel

OrbiMed Advisors had a $203 million close for its OrbiMed Israel Partners healthcare fund. The firm is continuing to raise money, working toward an undisclosed target. The Israeli government is an LP, contributing about $40...
Items per page:
1 - 10 of 10